Cost-effectiveness of abiraterone treatment in patients with castration-resistant prostate cancer who previously received docetaxel therapy

<p><strong>Background.</strong> Therapy for metastatic castration-resistant prostate cancer (CRPC) is a serious problem that requires significant public health care expenditures.</p><p><strong>Objective</strong>: to evaluate the cost-effectiveness of abirate...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: A. V. Rudakova, D. O. Meshkov, S. V. Mishugin
Fformat: Artigo
Iaith:Russo
Cyhoeddwyd: ABV-press 2014-11-01
Cyfres:Onkourologiâ
Pynciau:
castration-resistant prostate cancer
chemotherapy
docetaxel
abiraterone
survival
cost effectiveness
Mynediad Ar-lein:http://oncourology.abvpress.ru/index.php/oncur/article/view/383
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg